Cargando…
Increased urokinase and consumption of α(2)‐antiplasmin as an explanation for the loss of benefit of tranexamic acid after treatment delay
ESSENTIALS: Delayed treatment with tranexamic acid results in loss of efficacy and poor outcomes. Increasing urokinase activity may account for adverse effects of late tranexamic acid treatment. Urokinase + tranexamic acid produces plasmin in plasma or blood and disrupts clotting. α(2)‐Antiplasmin c...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334274/ https://www.ncbi.nlm.nih.gov/pubmed/30451372 http://dx.doi.org/10.1111/jth.14338 |